Alexion Pharmaceuticals, Inc

Add to watchlist
$181.9
Last updated:06/15/2021
ALXN: NASDAQ
Alexion Pharmaceuticals, Inc

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized m… Show more

P/E ratio
59.04x
vs. 13.77x forward

Price is 59.04x times more than EPS $3.08 which eaquals $181.9

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
443.3M
77.6M
-82.49%
2.4043B
+2998.32%
603.4M
-74.90%
Cashflow
Sum up money going in and out company
1.1156B
426M
-61.81%
2.0849B
+389.41%
3.0029B
+44.03%
Total liabilities
All combined debts and obligations
4.6902B
4.7666B
+1.63%
6.2728B
+31.60%
6.4518B
+2.85%
Stock exposure in ETFs
ETF
Percentage of ETF
Become a premium member and see all 25 ETFs that include this stock
Company profile
CEO
Dr. Ludwig N. Hantson
Market capitalization
Mega (40.09B)
ALXN price history
Loading price stock history...